Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BANX vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BANX Captures Overall Composite Edge (39.5 SELL vs 44.8 HOLD), While ACAD Leads 4–2 on Growth & Valuation Pillars

BANX Overall Winner 6-Pillar Tally: BANX 2 – 4 ACAD Matrix Metrics: BANX 4 – 5 ACAD

As of Nov 20, 2026, ArrowMark Financial Corp. (BANX) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (39.5/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. BANX trades at $18.79 (14.6x Forward P/E, 75.4% operating margin) versus ACAD at $17.11 (15.8x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. BANX 39.5/100 SELL), BANX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (75.4% vs. 10.2% operating margin) and revenue trajectory (-0.2% vs. +22.8% YoY).
  • Technical & Structure Timing Caution: BANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BANX vs ACAD
BANX NASDAQ Head-to-Head Winner
ArrowMark Financial Corp. Common Stock
Institutional Equity
$18.79
-0.74% 1D
Market Cap $183.4M
TTM Revenue $27M
Forward P/E 14.6x
Beta / 30D Vol 0.19β · 12% Vol
Unified Composite Score
39.5 / 100 SELL
Tech 28.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 29
RSI-14: 29.4 · SMA20: $19.50 · SMA50: $19.93
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
TTM Revenue $1.20B
Forward P/E 15.8x
Beta / 30D Vol 0.15β · 90% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $19.31 · SMA50: $20.80

6-Pillar Scorecard Institutional Category Breakdown (BANX 2 – 4 ACAD)

Columns: Metric · BANX · ACAD
1. Valuation Multiples ACAD
Forward P/E 14.6x 15.8x
Trailing P/E 17.7x 8.3x
PEG Ratio N/M N/M
EV / Revenue 6.9x 2.3x
2. Growth & Scale ACAD
Revenue Growth (YoY) -0.2% +22.8%
Earnings Growth (YoY) -58.1% -26.2%
TTM Revenue (USD) $27M $1.20B
Market Cap $183.4M $3.0B
3. Profitability & Quality BANX
Gross Margin 100.0% 63.9%
Operating Margin 75.4% 10.2%
Net Profit Margin 50.8% 30.1%
Return on Equity (ROE) 7.4% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) N/A $181M
Cash Flow Margin N/A 15.0%
Net Cash / Leverage $21.00 Book/Sh · 7.4% ROE $251M Net Cash
Dividend Yield 9.33% None (0.00%)
5. Options & Positioning BANX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 80.3% (14th %ile) 41.7% (6th %ile)
Put/Call OI Skew N/A 71.82x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 24.6% of Rev ($6.5M) 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Asset Management Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BANX (4) vs ACAD (5)
Institutional Metric BANX ACAD Criterion Row Edge
Market Capitalization
Scale
$183.4M $3.0B Larger Scale ACAD
Trailing P/E Ratio
Valuation
17.7x 8.3x Lower Multiple ACAD
Forward P/E Ratio
Valuation
14.6x 15.8x Lower Multiple BANX
Revenue Growth (YoY)
Growth
-0.2% +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
75.4% 10.2% Higher Margin BANX
Net Profit Margin
Profitability
50.8% 30.1% Higher Margin BANX
Return on Equity (ROE)
Capital Efficiency
7.4% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
8% ($18–$22) 8% ($16–$31) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.19β · 12% Vol 0.15β · 90% Vol Lower Realized Risk BANX
Unified Institutional Score
Composite Signal
39.5 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
$27M $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.9x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($21.00 Book/Sh · 7.4% ROE) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BANX +9.66 pp
BANX: -6.1% · ACAD: -15.76%
3M Horizon BANX +33.22 pp
BANX: -9.07% · ACAD: -42.29%
6M Horizon BANX +14.34 pp
BANX: -4.57% · ACAD: -18.91%
1Y Horizon BANX +14.77 pp
BANX: -11.16% · ACAD: -25.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BANX vs ACAD. Trailing 12-month operating profitability (BANX 75.4% vs ACAD 10.2%) and valuation multiples (BANX 14.6x vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

BANX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$27M
Gross Margin100.0%
Op. Margin75.4%
ROE / Fwd P/E7.4% · 14.6x
ACAD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.20B
Gross Margin63.9%
Op. Margin10.2%
ROE / Fwd P/E31.4% · 15.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BANX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 80.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BANX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 6th %ile
Put/Call OI Skew 71.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BANX Moat Profile High-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $183.4M market capitalization and 75.4% operating margin.
OpEx & R&D Reinvestment 24.6% of Rev ($6.5M)
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ BANX vs ACAD Key Questions & Quantitative Answers

As of Nov 20, 2026, ArrowMark Financial Corp. (BANX) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (39.5/100 SELL vs. 44.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. BANX trades at $18.79 (14.6x Forward P/E, 75.4% operating margin) versus ACAD at $17.11 (15.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. BANX 39.5/100 SELL), BANX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (75.4% vs. 10.2% operating margin) and revenue trajectory (-0.2% vs. +22.8% YoY). Technical & Structure Timing Caution: BANX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: BANX posts -0.2% YoY revenue growth and -58.1% YoY earnings growth on $27M TTM revenue (100.0% gross margin, 75.4% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, BANX generates $27M in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, BANX deploys 24.6% of Rev ($6.5M) (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. BANX trades at 14.6x Forward P/E, 17.7x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (unreported cash flow margin), whereas ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BANX (7.4% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BANX carries 80.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 12% Vol realized risk). By comparison, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.